A quote from a former long turned short regarding finances.
"Gerald told me personally that he has turned away many venture capitalists and high net private investors trying to buy restricted shares. His response to them is to go buy retail. I know 2 of these individuals, both are on iHub wink

We recently eliminated the toxic financing and cleaned up the balance sheet nicely. I would expect to see the benefits shortly."

Business plan looks pretty good to me. Current activities:
The upcoming activities related to Amarantus’ Parkinson’s disease program include:
• Create mammalian GMP production processes for MANF; the Company has sourced the expertise for these activities, and has started development of the supporting analytical and bioanalytical assays;
• Form a partnership agreement in the third quarter of 2013 with a firm specializing in Convection-enhanced delivery (CED) of drugs to the brain;
• Initiate non-human primate pharmacology studies in Parkinson's disease models in the second half of 2013 in order to establish an appropriate dosing regimen for human clinical studies;
• Potentially evaluate MANF gene therapy based upon upcoming developments in the field of neurotrophic factors for Parkinson’s disease, and the Company’s current patent position whereby the Company owns exclusive rights to MANF gene therapy applications in all vector systems.

Additional planned activities are expected to include:
• Conduct pharmacokinetic and pharmacodynamic (PK/PD) studies, with data available in the third quarter of 2013, to evaluate the biological properties of MANF when administered systemically, with data to be released as it becomes available;
• Conduct pharmacology studies in traumatic brain injury, ischemic heart disease, diabetes and certain other animal models in the third quarter of 2013, with data to be released as it becomes available;
• Evaluate MANF in a variety of animal models of orphan diseases in the third quarter of 2013 that represent significant market opportunities, and where there is limited or very limited competition;
• Initiate MANF toxicology studies upon development of a master cell bank of MANF protein material as one of the final pre-IND steps;
• File an IND in 2014.

I don't feel alienated. If someone does then they should move on. It's just that simple.

Dr. Jerry as one AMBS long to another, do you have any estimate as to the length of time it will take BD to do the analysis on the LymPro test? I respect your opinions. AMBS say's 3rd Quarter. Seems to soon to me.

New drug application to the FDA. Look here, Has AMBS not done what they have said they were going to do?
John W. Commissiong, Ph.D., Chief Scientific Officer of Amarantus. “We are very pleased that independent research is contributing to the further understanding of MANF. The protective activity demonstrated by this independent work clearly suggests MANF may have utility in the treatment of conditions such as stroke, post-stroke recovery, Traumatic Brain Injury and concussion, as well as having relevance to the use of MANF in Parkinson’s disease. We continue to conduct additional experiments with MANF in support of a planned Investigational New Drug (IND) application to the FDA.”

Mid-west Corn association studying MANF? I've heard some whoppers but that's a whopper of a tail. What are they studying to see if POP's in cocoanut oil. !! Ha Ha Ha I guess he has no clue what MANF is.

Current activities:
The upcoming activities related to Amarantus’ Parkinson’s disease program include:
• Create mammalian GMP production processes for MANF; the Company has sourced the expertise for these activities, and has started development of the supporting analytical and bioanalytical assays;
• Form a partnership agreement in the third quarter of 2013 with a firm specializing in Convection-enhanced delivery (CED) of drugs to the brain;
• Initiate non-human primate pharmacology studies in Parkinson's disease models in the second half of 2013 in order to establish an appropriate dosing regimen for human clinical studies;
• Potentially evaluate MANF gene therapy based upon upcoming developments in the field of neurotrophic factors for Parkinson’s disease, and the Company’s current patent position whereby the Company owns exclusive rights to MANF gene therapy applications in all vector systems.

Additional planned activities are expected to include:
• Conduct pharmacokinetic and pharmacodynamic (PK/PD) studies, with data available in the third quarter of 2013, to evaluate the biological properties of MANF when administered systemically, with data to be released as it becomes available;
• Conduct pharmacology studies in traumatic brain injury, ischemic heart disease, diabetes and certain other animal models in the third quarter of 2013, with data to be released as it becomes available;
• Evaluate MANF in a variety of animal models of orphan diseases in the third quarter of 2013 that represent significant market opportunities, and where there is limited or very limited competition;
• Initiate MANF toxicology studies upon development of a master cell bank of MANF protein material as one of the final pre-IND steps;
• File an IND in 2014.

Someone sold 3000 at .031.Below the bid ha ha ha I bet that really put the scare into the longs. Ha Ha Ha

I find it interesting that the Becton Dickinson and AMBS agreement did not have the financial terms disclosed. You can only summize that there is more to this then we know.

The company is very busy following it's business plan.
Engageing BD Bioscience, a preclinical study in China, presenting at the C$CT Concussion Awareness Summit, IND application to the FDA. Doesn't sound like a scam to me as some have chattered.

Everday someone dumps the share price in the last few minutes of trading. Can you say manipulation. They are holding the price down for some reason. The longs will win this in the future. To much happening to keep it down! imo

The tests require funding. I'm not saying they have but so what if they sell a little stock for operations. If you are here for a short flip stop your whining and please leave and go somewhere else. Someone will serve you some MANF when its ready. Like it or not it will take some time to get the results. But they could be huge!!! imo

Look at the upcoming activities for AMBS:
The upcoming activities related to Amarantus’ Parkinson’s disease program include:
• Create mammalian GMP production processes for MANF; the Company has sourced the expertise for these activities, and has started development of the supporting analytical and bioanalytical assays;
• Form a partnership agreement in the third quarter of 2013 with a firm specializing in Convection-enhanced delivery (CED) of drugs to the brain;
• Initiate non-human primate pharmacology studies in Parkinson's disease models in the second half of 2013 in order to establish an appropriate dosing regimen for human clinical studies;
• Potentially evaluate MANF gene therapy based upon upcoming developments in the field of neurotrophic factors for Parkinson’s disease, and the Company’s current patent position whereby the Company owns exclusive rights to MANF gene therapy applications in all vector systems.

Additional planned activities are expected to include:
• Conduct pharmacokinetic and pharmacodynamic (PK/PD) studies, with data available in the third quarter of 2013, to evaluate the biological properties of MANF when administered systemically, with data to be released as it becomes available;
• Conduct pharmacology studies in traumatic brain injury, ischemic heart disease, diabetes and certain other animal models in the third quarter of 2013, with data to be released as it becomes available;
• Evaluate MANF in a variety of animal models of orphan diseases in the third quarter of 2013 that represent significant market opportunities, and where there is limited or very limited competition;
• Initiate MANF toxicology studies upon development of a master cell bank of MANF protein material as one of the final pre-IND steps;
• File an IND in 2014.

FDA application soon!! John W. Commissiong, Ph.D., Chief Scientific Officer of Amarantus. “We are very pleased that independent research is contributing to the further understanding of MANF. The protective activity demonstrated by this independent work clearly suggests MANF may have utility in the treatment of conditions such as stroke, post-stroke recovery, Traumatic Brain Injury and concussion, as well as having relevance to the use of MANF in Parkinson’s disease. We continue to conduct additional experiments with MANF in support of a planned Investigational New Drug (IND) application to the FDA.”

Alot happening behind the scenes. Nobody here knew testing was going on in China. What else is going on? I'm betting a bunch!! imo

You are correct there is HUGE hope for MANF and a HUGE market.

China will be a HUGE market for MANF. AMBS will be a global company. Now getting test results from several sources.

Founded by an American Qilu Hospital of Shandong University, in Jinan, China.
http://www.qiluhospital.com/site2/eng/09/10101.shtml

"planned Investigational New Drug application to the FDA" soon to come!!!

Varifying results!! "We continue to conduct additional experiments with MANF in support of a planned Investigational New Drug (IND) application to the FDA.”
All part of the larger plan that you flippers can't see!!!!

John W. Commissiong, Ph.D., Chief Scientific Officer of Amarantus. “We are very pleased that independent research is contributing to the further understanding of MANF. The protective activity demonstrated by this independent work clearly suggests MANF may have utility in the treatment of conditions such as stroke, post-stroke recovery, Traumatic Brain Injury and concussion, as well as having relevance to the use of MANF in Parkinson’s disease. We continue to conduct additional experiments with MANF in support of a planned Investigational New Drug (IND) application to the FDA.”

More great news!!! Amarantus Reports Positive Results on MANF Neuroprotective Properties Demonstrated in Preclinical Study in China

“The data on MANF continues to return more favorable results than other molecules currently in clinical development as disease-modifying treatments for Parkinson’s disease,” said Dr. Joseph Rubinfeld, Amgen co-founder and current member of the Company’s Board of Advisors.

"Financial terms were not disclosed" This has me wondering what the terms were and why they were not disclosed. Maybe BD will do the testing for nada and then after varifying the results we become one!!!! Lets face it AMBS has know about working with BD even before the White paper inadvertently show them onboard.

Gerald doing this right IMO. Get all the testing with a reputable company completed and keep all the rights to the product. Sure it costs money but if it works out like the company thinks, MANF is a 500 million + company. Why share that at this point in time?

We need the 10-Q!!!

Amarantus and Brewer Sports International Announce Details and Speaker List for Concussion Awareness Summit (#C4CT Summit) being held at the Minneapolis Club in Minnesota on June 21, 2013.
https://twitter.com/brewersports

BD adds creditability to the testing. Big step up.

The upcoming activities related to Amarantus’ Parkinson’s disease program include:
• Create mammalian GMP production processes for MANF; the Company has sourced the expertise for these activities, and has started development of the supporting analytical and bioanalytical assays;
• Form a partnership agreement in the third quarter of 2013 with a firm specializing in Convection-enhanced delivery (CED) of drugs to the brain;
• Initiate non-human primate pharmacology studies in Parkinson's disease models in the second half of 2013 in order to establish an appropriate dosing regimen for human clinical studies;
• Potentially evaluate MANF gene therapy based upon upcoming developments in the field of neurotrophic factors for Parkinson’s disease, and the Company’s current patent position whereby the Company owns exclusive rights to MANF gene therapy applications in all vector systems.

Additional planned activities are expected to include:
• Conduct pharmacokinetic and pharmacodynamic (PK/PD) studies, with data available in the third quarter of 2013, to evaluate the biological properties of MANF when administered systemically, with data to be released as it becomes available;
• Conduct pharmacology studies in traumatic brain injury, ischemic heart disease, diabetes and certain other animal models in the third quarter of 2013, with data to be released as it becomes available;
• Evaluate MANF in a variety of animal models of orphan diseases in the third quarter of 2013 that represent significant market opportunities, and where there is limited or very limited competition;
• Initiate MANF toxicology studies upon development of a master cell bank of MANF protein material as one of the final pre-IND steps;
• File an IND in 2014.

BD may want a part of AMBS!!!

Gerald not worried about the "Chatterboxes" on IHUB. He is working on a cure for diseases of the brain!!!!

Doom and Gloomers do you really think BD would hook up with AMBS if the company was a scam. I don't think so and hooked up with AMBS a long time ago!! BIG NEWS!!!!!

I knew about it at 6:30 am the morning it came out.(Ref New target areas) What I was getting at is the IHUB web page that posts the news doesn't get updated. It's still not showing up. the last "news" post was the "Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)".

I was wondering where you went. Why don't you ask the company then share the answer with all of us.

T minus 10 and waiting!!!!!

If we get news it probably won't be posted here. The last company news release of 5/30 still hasn't been updated here yet. Whoever is responsible for the news updates on the page is doing a lousy job of it.
CRGC news was always updated as soon as it was released.

The upcoming activities related to Amarantus’ Parkinson’s disease program include:
• Create mammalian GMP production processes for MANF; the Company has sourced the expertise for these activities, and has started development of the supporting analytical and bioanalytical assays;
• Form a partnership agreement in the third quarter of 2013 with a firm specializing in Convection-enhanced delivery (CED) of drugs to the brain;
• Initiate non-human primate pharmacology studies in Parkinson's disease models in the second half of 2013 in order to establish an appropriate dosing regimen for human clinical studies;
• Potentially evaluate MANF gene therapy based upon upcoming developments in the field of neurotrophic factors for Parkinson’s disease, and the Company’s current patent position whereby the Company owns exclusive rights to MANF gene therapy applications in all vector systems.

Additional planned activities are expected to include:
• Conduct pharmacokinetic and pharmacodynamic (PK/PD) studies, with data available in the third quarter of 2013, to evaluate the biological properties of MANF when administered systemically, with data to be released as it becomes available;
• Conduct pharmacology studies in traumatic brain injury, ischemic heart disease, diabetes and certain other animal models in the third quarter of 2013, with data to be released as it becomes available;
• Evaluate MANF in a variety of animal models of orphan diseases in the third quarter of 2013 that represent significant market opportunities, and where there is limited or very limited competition;
• Initiate MANF toxicology studies upon development of a master cell bank of MANF protein material as one of the final pre-IND steps;
• File an IND in 2014.

2 to 1 buys today. Good accumilation going on.

Over a 300,000 shares in the 1st 20 minutes of trading!!

Stock getting some upward movement this morning. Nice to see. Maybe news is brewing!!